<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04525209</url>
  </required_header>
  <id_info>
    <org_study_id>2020-08-20</org_study_id>
    <nct_id>NCT04525209</nct_id>
  </id_info>
  <brief_title>Integrative Proteomic Characterization of Pancreatic Ductal Adenocarcinoma</brief_title>
  <official_title>Integrative Proteomic Characterization of Pancreatic Ductal Adenocarcinoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ruijin Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Ruijin Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      A large-scale, high-throughput, multi-dimensional comprehensive study of PDAC multiomics will&#xD;
      be carried out. In this study, clinical specimens of resected PDAC collected by our research&#xD;
      group from 2017 to 2019 will be selected as research objects.Tumor tissues and their adjacent&#xD;
      non-tumor tissues from more than 200 PDAC patients are expected to be used for genome,&#xD;
      transcriptome sequencing and mass spectrometry analysis of proteome and phosphorylated&#xD;
      proteome.Combined with the data results of multiomics, bioinformatics analysis and network&#xD;
      database information, we will clarify the relationship between multiomics of pancreatic&#xD;
      cancer and established the new subtyping of pancreatic cancer proteome. A molecular landscape&#xD;
      of the progression of pancreatic cancer at the genome-transcriptome-proteome level provides&#xD;
      new therapeutic targets to improve the prognosis of this deadly disease.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">October 1, 2020</start_date>
  <completion_date type="Anticipated">December 31, 2022</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2022</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Integrative Proteomic Characterization of PDAC</measure>
    <time_frame>Two yeaers</time_frame>
    <description>The genome-transcriptome proteome level provides a molecular landscape of the progression of pancreatic cancer, providing new therapeutic targets to improve the prognosis of PDAC</description>
  </primary_outcome>
  <enrollment type="Anticipated">200</enrollment>
  <condition>Tumor Tissues and Non-tumor Tissues From PDAC Patients Were Used for Genomic and Transcriptome Sequencing Analysis and Proteomics and Phosphorylated Proteomics</condition>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>No intervention</intervention_name>
    <description>No intervention</description>
  </intervention>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      PDAC tumor and Non-tumor DNA, RNA, protein&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Chinese PDAC patients&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. The diagnosis of pancreatic cancer was confirmed by histological examination or fine&#xD;
             needle aspiration cytology;&#xD;
&#xD;
          2. The tumor was graded according to THE WHO standard, and the tumor stage was graded&#xD;
             according to the TNM stage;&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. The inclusion criteria of the above groups were not met;&#xD;
&#xD;
          2. There are few tissue specimens, only enough for clinical diagnosis;&#xD;
&#xD;
          3. Patients are unwilling to conduct follow-up study;&#xD;
&#xD;
          4. For the new diagnosed patient, radiotherapy or chemotherapy have been given in the&#xD;
             previous three months;&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Hao Chen, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Ruijin Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Hao Chen, MD</last_name>
    <phone>13003135899</phone>
    <email>haochendr@126.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Lingxi Jiang, Ph.D</last_name>
    <phone>13818826142</phone>
    <email>jlx12120@rjh.com.cn</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>RUIJIN Hospital</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <zip>200025</zip>
        <country>China</country>
      </address>
    </facility>
    <contact>
      <last_name>Jian Li, Ph.D</last_name>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <reference>
    <citation>Gao Q, Zhu H, Dong L, Shi W, Chen R, Song Z, Huang C, Li J, Dong X, Zhou Y, Liu Q, Ma L, Wang X, Zhou J, Liu Y, Boja E, Robles AI, Ma W, Wang P, Li Y, Ding L, Wen B, Zhang B, Rodriguez H, Gao D, Zhou H, Fan J. Integrated Proteogenomic Characterization of HBV-Related Hepatocellular Carcinoma. Cell. 2019 Oct 3;179(2):561-577.e22. doi: 10.1016/j.cell.2019.08.052. Erratum in: Cell. 2019 Nov 14;179(5):1240.</citation>
    <PMID>31585088</PMID>
  </reference>
  <results_reference>
    <citation>Cancer Genome Atlas Research Network. Electronic address: andrew_aguirre@dfci.harvard.edu; Cancer Genome Atlas Research Network. Integrated Genomic Characterization of Pancreatic Ductal Adenocarcinoma. Cancer Cell. 2017 Aug 14;32(2):185-203.e13. doi: 10.1016/j.ccell.2017.07.007.</citation>
    <PMID>28810144</PMID>
  </results_reference>
  <verification_date>August 2020</verification_date>
  <study_first_submitted>August 20, 2020</study_first_submitted>
  <study_first_submitted_qc>August 20, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">August 25, 2020</study_first_posted>
  <last_update_submitted>August 20, 2020</last_update_submitted>
  <last_update_submitted_qc>August 20, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">August 25, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Ruijin Hospital</investigator_affiliation>
    <investigator_full_name>HAOCHEN</investigator_full_name>
    <investigator_title>Chen Hao</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Adenocarcinoma</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

